Human papillomavirus self-testing among unscreened and under-screened Māori, Pasifika and Asian women in Aotearoa New Zealand: A preference survey among responders and interviews with clinical-trial nonresponders

Susan M. Sherman PhD, Reader in Psychology1 | Naomi Brewer PhD, Research Fellow2 | Karen Bartholomew MbChB, MPH, Director Health Outcomes3,4 | Collette Bromhead PhD, Senior Lecturer5 | Sue Crengle PhD, Professor Hauora Māori6 | Chris Cunningham PhD, Professor Māori and Public Health2 | Jeroen Douwes PhD, Professor2 | Sunia Foliaki MBBS, PhD, Associate Professor2 | Jane Grant RN, Nurse Specialist3,4 | Anna Maxwell BA, RN, MPH, Research Coordinator3,4 | Georgina McPherson DHSc, Nurse Practitioner3 | Nina Scott FNZCPHM, Director of Māori Equity Strategy & Research3,7 | Helen Wihongi PhD, Director Māori Health Research3,4 | John D. Potter MBBS, PhD, Professor2

Abstract

Introduction: Māori, Pasifika and Asian women are less likely to attend cervical screening and Māori and Pasifika women are more likely to be diagnosed with later-stage cervical cancer than other women in Aotearoa New Zealand. This study—with under-screened women taking part in a randomized-controlled trial comparing self-testing and standard screening—explored the acceptability of a human papillomavirus (HPV) self-test kit and the preferred method for receiving it.

Methods: Māori, Pasifika and Asian women (N=376) completed a cross-sectional postal questionnaire. Twenty-six women who had not accepted the trial invitation were interviewed to understand their reasons for nonparticipation.

Results: Most women found the self-test kit easy and convenient to use and reported that they did not find it painful, uncomfortable or embarrassing. This was reflected in the preference for a self-test over a future smear test on the same
1 | INTRODUCTION

Globally, cervical cancer is the fourth most common cancer affecting women, with around 570,000 diagnoses and 311,000 deaths in 2018. In Aotearoa New Zealand, there were 190 diagnoses and 72 deaths in 2018; cervical cancer is the fourth most common cancer in women aged 15–44 years. Māori women have a 1.7× higher incidence of this cancer (age-standardized rate of 9.4 cases per 100,000) than non-Māori women (5.4 cases per 100,000), and the mortality rate is 2.7 times higher for Māori women (3.0 deaths per 100,000) than non-Māori women (1.1 cases per 100,000). A review of cervical cancer incidence in 2013–2017 showed that, for those women who were screened in the 6–84 months before diagnosis, 40% of Māori women and 53% of Pasifika women had a high-grade cervical cytology sample compared to 16% of European women, suggesting missed opportunities for prevention or earlier diagnosis. One of the key recommendations of the review was that resources be provided to improve access to screening and treatment of cervical precancer for Māori women.... Intervention strategies should take into consideration both the practical and cultural needs of these women/wāhine (emphasis added).

High-risk human papillomavirus (HPV) types, primarily transmitted by sexual contact, are detected in more than 90% of cervical cancers. Persistent infection with high-risk HPV can result in precancerous changes in cervical cells, which, if left untreated, can progress to cervical cancer. Currently, the National Cervical Screening Programme (NCSP) in Aotearoa New Zealand recommends cervical screening every 3 years for women aged 25–69 years, with cytology as the primary test. HPV testing is an alternative primary screening test and many countries have already implemented this in their programmes. The overall 3-year screening coverage in Aotearoa New Zealand decreased from 72.2% in March 2019 to 70.2% in March 2021 against a target of 80%. For Māori women, the decrease was from 64.6% to 61.2%; for Pasifika women, it was 69.4%–63.1%; and for Asian women, it was 62.4%–61.4%. The existing inequitable outcomes for Māori and Pasifika women are likely to worsen if these declines in screening continue. Moving to a system of primary HPV screening provides the possibility of offering women the option of HPV self-testing. This can be done in women’s homes or in a clinic setting and may address patient/client- and provider-related barriers to screening that have arisen due to structural and systemic biases.

A previous study that explored barriers to cervical screening for Māori women, as well as hypothetical acceptability of HPV self-testing, found that the primary barriers to conventional, more invasive screening were lack of time/other commitments, fear of discomfort or pain and that some Māori women consider this area to be tapu (sacred) and, therefore, in some cases, screening caused feelings of embarrassment. In that study, 61.2% of women said that they would prefer an HPV self-test to either a clinician-taken HPV test or conventional screening and 73.3% said they would be likely or very likely to self-test if it were offered. A pilot study exploring acceptability found that 66% of under-screened women aged 25–69 years, with cytology as the primary test. HPV testing is an alternative primary screening test and many countries have already implemented this in their programmes.

Whereas whakāmā (a feeling of being at a disadvantage, often a cultural disadvantage) in the interpretation of women’s reporting about the invasiveness of vaginal examinations/cytology test, with the use of these terms seen to be victim blaming/deficit framing. We deliberately refer here to the invasive nature of the test to reflect that it is the test that is problematic.
Māori and Pasifika women preferred to self-test after trying a device.10 Subsequently, two randomized-controlled trials (RCTs) have been conducted to explore HPV self-testing with under-screened or never-screened women, both with a focus on Māori. In the first study, women in the intervention arm of the RCT were offered an HPV self-test, although they could opt instead for a clinician-taken sample or a smear test. The self-test could be done at home, in the clinic or at a community centre. The control arm was usual care, so the women were offered a clinician-taken smear test. Of women in the self-test arm of the RCT, 59% were screened, compared to 22% of those in the usual-care arm, suggesting that an offer of self-testing could substantially increase screening uptake among Māori women.11

A second, larger, RCT conducted by our research team10 was preceded by a feasibility study,12 which focused on stakeholder co-design and testing the cultural appropriateness of materials. Between 2018 and 2020, an open-label, three-arm, community-based, randomized-controlled trial in which unscreened or under-screened (≥5 years overdue) Māori, Pasifika and Asian women from Auckland were invited for cervical screening was undertaken. The three trial arms were as follows: usual care, in which women were invited to attend a clinic for a standard smear sample; clinic-based self-testing, in which women were invited to take a self-test at their usual general practice; and mail-out self-testing, in which women were posted a kit and invited to take a self-test at home. This showed that, although screening uptake was lower than in the first RCT, self-testing uptake was again statistically significantly preferred over usual care, with the highest participation in the mail-out self-test arm.13

Here, we report the findings from the acceptability survey that was given to women participating in the self-testing arms of the second RCT and nested sub-study in which some nonresponding women were offered opportunistic self-sampling when they presented to the clinic for other reasons,10 as well as the findings from a telephone survey conducted with nonresponding women. The main aims of the survey and interviews were to explore the acceptability of the HPV self-test2 kit; to determine what preferences women had for invitation, sample return and follow-up methods; to establish whether the level of information in the participant material was appropriate and acceptable for Māori, Pasifika and Asian women; and to determine whether further localization or refinement was required.

2 | METHOD

2.1 | Design

We conducted a paper-based cross-sectional survey throughout the main trial and nested sub-study, which recruited women between June 2018 and May 2020. We also conducted telephone interviews with women who did not respond to the invitation to take part in the trial, to understand their reasons for nonparticipation.

2.2 | Participants

All Māori, Pasifika and Asian women who were invited to take part in one of the two self-testing arms of the RCT13 were given a survey to complete about their experience of self-testing, which they completed at home or in the clinic, depending on where they completed the self-testing. The women were all aged 30-69 years, were resident in Waitematā or Auckland District Health Board (DHB) areas and had never been screened or were overdue (≥5 years) for cervical screening.

Before beginning this trial, we completed a feasibility and acceptability study, where we conducted ethnic-specific focus groups with a health-literacy expert to develop and improve the information and its presentation.12 Women were identified through a routinely available national data-match process between Primary Health Organizations (organizations responsible for primary care) and the NCSP, where the screening status of enrolled women is updated monthly.10 They were deemed to be unscreened or under-screened if no screening had been recorded for the last 5 years.

Women were invited through their usual primary care provider (in partnership with the research team). Women in the self-testing at home arm were posted the kit, instructions and reply envelope along with the questionnaire. The information sent included a link to the webpage with translated study documents and the study video clips. Women in the clinic-based self-testing arm were posted an invitation to the clinic with booking details, completed nurse consent when they attended the clinic and completed the paper-based questionnaire at the time of the test. Women in the opportunistic sub-study were sent a letter or text informing them that they were now able to self-test at their clinic or request that a self-testing kit be mailed to them, both for a limited period of time. In addition, an alert was put on the primary care dashboard so that if they attended for any other reason, they would be offered a self-test in the study period.

A random sample of women who were invited to the RCT but did not take part (nonresponders) was contacted by telephone to take part in a telephone interview. The aim was to recruit equal numbers of women from each ethnicity and study group.

2.3 | Measures—Survey

The survey items were localized and developed (based on feedback) from the Australian iPap study responders’ posttest questionnaire14 with permission from the iPAP investigators and these, along with some additional questions, are detailed below.

2.3.1 | Questions about the cervical screening test

All women were asked about their experience of the self-test kit; whether the instructions were clear and easy to understand; whether they had watched the study video clips (the women were directed to a webpage with clips that had subtitles in several languages: Te Reo...
2.3.2 | Socio-demographic questions

The final part of the survey included a series of socio-demographic questions regarding highest level of schooling; household income; which generation of their family came to Aotearoa New Zealand; whether English is their first language; and whether they identify as Māori.

2.4 | Measures—Interviews

A structured interview guide was used with nonresponders to explore whether they had received the invitation to the trial and their reasons for not taking part as detailed in Table 1.

### Table 1: Interview guide for nonresponders to the clinical trial

| Question                                           | Example script                                                                 | Action                                      |
|-----------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------|
| Did they receive the invitation?                    | I'm calling from the Women's Health self-test study—did you receive the invitation we sent you? | If no, brief explanation and offer to send kit. |
|                                                     |                                                                               | Update address details                      |
| If yes, enquire into their response to the invitation for example: | Did you get a chance to have a look at it?                                   | Record any comments.                        |
| • Was the invitation clear?                         | How did you find the info we sent you?                                       | Offer follow-up call from nurse if appropriate. |
| • Did they understand what they were being asked to do? | Was it clear what you were being invited to do?                              |                                             |
| • Did they decide not to participate?               | Was there a reason that you didn't do the self-test?                         |                                             |
| If appropriate, find out what would have made them participate. | Do you have any suggestions?                                                  | Record any comments.                        |
|                                                     | Is there anything we could have done differently?                             |                                             |

2.5 | Analysis

The survey data are summarized using descriptive statistics. We ran a series of Pearson’s $\chi^2$ tests to compare the reasons for not ever or not recently having had a smear test across ethnicities.

To analyse the open-ended responses to survey questions and the telephone interviews, we undertook content analysis using an emergent-coding approach, whereby codes were identified from the data rather than a priori. The interview data consist of short accounts of the conversation documented by the Māori interviewer making the call.

Ethnicity data were collected and categorized in line with the HIS0 10001:2017 Ethnicity Data Protocols, whereby respondents self-identify and responses are categorized according to Statistics NZ descriptors (https://www.health.govt.nz/publication/hiso-100012017-ethnicity-data-protocols). We used a prioritized output (if multiple ethnicities are identified, only one is included in the analyses), ordered Māori > Pasifika > Asian > Other, as per the Ethnicity-data standards.

3 | RESULTS

The results reported below are from those women who responded to the invitation to take part in the study.

3.1 | Interviews with nonresponders

Interviews with nonresponders were also conducted. One hundred and twelve contact attempts were made, at different times of the day. In total, 26 women were interviewed; 16 of these were from the self-test in the clinic group (Māori, N = 4; Pasifika, N = 4; Asian, N = 6) and 12 were from the self-test at home group (Māori, N = 4; Pasifika, N = 4; Asian, N = 4). The content analysis of the notes made by the
3.2 | Survey

In total, 376 women (75.7% of women who returned their test) completed the survey (mean age, 46.5 years; SD = 10.6; range, 30–71). Participants’ characteristics are presented in Table 2.

3.3 | Using the self-test kit

Women were asked to indicate the extent to which they agreed with a series of statements about the HPV self-test kit. The responses are presented in Table 3.

In an additional question, of the 354 women who answered the question, 99.4% (N = 352) said that the self-test kit instructions were clear and easy to understand, with only 2 women indicating that they were not. Of the 358 women who answered the question, 78.5% (N = 281) said that they had not watched the video clips, while 21.5% (N = 77) said they had watched the video clips. The videos watched were About the HPV self-test study (N = 59); How to take part in the study (N = 50); How to do the test (N = 58); Getting your test results (N = 44); and About Cervical Screening And Your Rights (N = 44). Sixty-seven women indicated that the video clips were helpful, with just five women saying they were not.

Forty-two women provided responses other than N/A or ‘I didn’t watch them’ to the open-ended question asking for comments about the video clips (see the Supporting Information).

3.4 | Comparison of the self-test kit with the previous smear test

Women who had previously had a smear test were asked to compare this with the self-test kit and their responses are presented in Supporting Information: Table S1. The self-test was found to be easier, more convenient, less embarrassing and less uncomfortable by all groups. Women were less clear about the comparative accuracy of the two tests.

3.5 | Barriers to smear test

The number and percentage of reasons for not ever or not recently having had a smear test are presented in Table 4.

Forty-one women provided a free-text self-reported reason for not having had a smear test (see the Supporting Information).
Women were asked to identify whether they would prefer to have a doctor or nurse do the test in the future or whether they would prefer to do it themselves and then to identify the two main reasons for choosing that answer. In total, 18 women (4.8%) indicated that they would prefer a doctor or nurse to take the test; 287 women (76.3%) indicated that they would prefer to take their own test at home; 63 women (16.8%) indicated that they would prefer to take their own test at a medical clinic; 3 women (0.8%) said they did not intend to do a test again; and 7 women (1.9%) did not know what they would prefer. 18 women left the
question blank. The reasons for their preferences are presented in Supporting Information: Table S2, with the top reason for preferring a doctor or nurse to take the test being that the test is accurate and the top two reasons for preferring a self-test being that it is less embarrassing and simple to do.

Women’s preferences for receiving and returning the self-test kit if they used it in the future are presented in Table 5. If the self-test kit were to be mailed, 67.0% (N = 252) said that they would prefer the kit to be automatically sent the next time they were due for their smear test, whereas 23.4% (N = 88) said that they would prefer to receive a letter or call first; 2.1% (N = 8) said that they would prefer to order the kit online from a health professional. 28 women did not answer the question.

### TABLE 4

| Question                                    | Māori  | Pasifika | Asian  | N (%)   |
|---------------------------------------------|--------|----------|--------|---------|
| A test from a nurse or doctor is embarrassing<sup>b</sup> | 60 (55.6) | 47 (44.8) | 57 (35.0) | 164 (43.6)<sup>***</sup> |
| A smear test from a nurse or doctor is too painful or uncomfortable<sup>b</sup> | 40 (37.0) | 35 (33.3) | 47 (28.8) | 122 (32.4)<sup>***</sup> |
| It is hard to find the time to have a test<sup>b</sup> | 33 (30.6) | 37 (35.2) | 49 (30.1) | 119 (31.6)<sup>***</sup> |
| I don’t think I need a test                 | 17 (15.7) | 19 (18.1) | 41 (25.2) | 77 (20.5) |
| I don’t feel comfortable asking for a test from my nurse or doctor | 29 (26.9) | 21 (20.0) | 24 (14.7) | 74 (19.7) |
| I don’t know if or when I should have a test | 13 (12.0) | 21 (20.0) | 30 (18.4) | 64 (17.0) |
| I have had a bad experience in the past having a test | 29 (26.9) | 17 (16.2) | 15 (9.2) | 61 (16.2) |
| I am not having sex                         | 14 (13.0) | 16 (15.2) | 30 (18.4) | 60 (16.0) |
| It is hard to find or get an appointment with the right nurse or doctor | 9 (8.3) | 11 (10.5) | 8 (4.9) | 28 (7.4) |
| It is hard to travel to an appointment      | 5 (4.6) | 6 (5.7) | 15 (9.2) | 26 (6.9) |
| It is too expensive to have a test          | 7 (6.5) | 4 (3.8) | 9 (5.5) | 20 (5.3) |
| I have never had sex                        | 5 (4.6) | 3 (2.9) | 11 (6.7) | 19 (5.1) |
| I have not received a reminder letter to have a test | 5 (4.6) | 3 (2.9) | 11 (6.7) | 19 (5.1) |
| It is hard to find a nurse or doctor of the right sex | 10 (9.3) | 3 (2.9) | 6 (3.7) | 19 (5.1) |
| My nurse or doctor has not suggested a test | 2 (1.9) | 1 (1.0) | 10 (6.1) | 13 (3.5) |
| It is hard to find a nurse or doctor who speaks my language | 0 (0.0) | 2 (3.1) | 5 (1.9) | 7 (1.9) |
| I have had a hysterectomy                   | 3 (2.8) | 1 (1.0) | 3 (1.8) | 7 (1.9) |
| It is hard to find a nurse or doctor of the right ethnicity | 1 (0.9) | 3 (2.9) | 2 (1.2) | 6 (1.6) |
| I don’t think test results are accurate enough | 0 (0.0) | 4 (3.8) | 1 (0.6) | 5 (1.3) |
| Rather not say                              | 3 (2.8) | 4 (3.8) | 2 (1.2) | 9 (2.4) |

Note: Multiple selections were possible.
<sup>a</sup>Percentage is of all 376 participants, but multiple responses were allowed and included.
<sup>b</sup>The top three reasons were also the most common responses from the 176 women who provided a main reason for lack of attendance from a list of options.
<sup>***</sup>p < .05 indicating a statistically significant effect of ethnicity on responses using a 3(ethnicity) × 2(selected reason or not) Pearson χ² test.
embarrassing. This was also reflected in the preference for a self-test over a future smear test on the grounds of ease, convenience, comfort and reduced embarrassment by most women who had previously had a smear test.

The only area of uncertainty around the self-test kit was related to the perceived accuracy of the self-test. A substantial minority (24%) were not confident or not sure that they had performed the test correctly. Furthermore, more than half the women (65%) who had previously had a smear test indicated that they were unsure whether the self-test kit or smear test was more accurate. In a focused literature review exploring the acceptability, feasibility and uptake of HPV self-testing among so-called hard-to-reach women across the world between 1997 and 2015, a key barrier to self-testing reported was a concern about sampling accuracy, including performing the procedure correctly.17 This barrier was reiterated in a more recent scoping review of research exploring HPV self-testing in Indigenous communities.18 The provision of more information addressing these areas may allay women's concerns. Most women in our study (76%) indicated that they would prefer to take a self-test at home or in a clinic (17%) rather than having a clinician do the test (5%) and the main reasons for this were reduced embarrassment, the simplicity of the test and not needing an appointment.

It is important to note that some of the findings differed by ethnicity. For example, although the three main reasons for not ever or not recently having had a smear test were the same for each group, the percentage of women from each group who reported these differed. For example, more Māori women than Pasifika women and more Pasifika women than Asian women reported embarrassment or pain or discomfort as a reason, while more Asian women than Māori or Pasifika women reported time as a reason. These and the other differences should be used to inform the design of information and educational materials to support HPV primary screening and self-testing that target at-risk groups.

The findings highlight areas where more information may be useful to increase uptake. For example, most women in our survey did not know whether the self-test or smear test was more accurate, 20% did not think they needed a test and, relatively, 16% reported not having the test because they were not having sex. Our findings also provide some clear insights into women's preferences, which should be used to inform the implementation of HPV primary screening and self-testing. Most women (72%) would prefer to receive a self-test kit mailed to their home, although some women would prefer to collect it from a clinic to do at the clinic (12%) or at home (10%). Importantly, if the test were to be mailed to their home, although most women (67%) would be happy for this to happen automatically, a sizable minority (23%) would prefer to receive a letter or call first. In relation to returning the kit, findings were more mixed. Some women would prefer to return the test by courier, some would prefer to return it to a clinic and others to a pharmacy or community laboratory. A range of options would provide the best rate of return, which is consistent with research that showed that a community laboratory drop-off alternative to postal return increased participation in New Zealand's Bowel Screening Pilot.19

As HPV self-testing is introduced, it will be important that these preferences are taken into account to maximize uptake of self-testing. A new purpose-built NCSP population register should allow recording of preferences for invitation and recall.

Maximizing access to self-testing can also be informed by our phone calls with nonresponders, which revealed that, although most had received the test kit, there were a variety of reasons for not doing the test, including not wanting to do it, being too busy or forgetting (see the Supplementary Materials). Follow-up phone calls were very time-consuming, so further research could investigate ways to maximize uptake of unsolicited self-testing kits, possibly with the use of advance notification that the kit was being sent and follow-up reminder letters, texts or calls.

The aforementioned scoping review of research exploring HPV self-testing in Indigenous communities covered the years 1993 to 2018 and just 19 studies, including grey literature, fulfilled the criteria18; however, none of these were from Aotearoa New Zealand. The study reported here builds on previous research,10,16 as well as

| Preference                                      | Māori (%) | Pasifika (%) | Asian (%) | N*  |
|-----------------------------------------------|-----------|--------------|-----------|-----|
| Receive self-test kit by mail***              | 83 (76.9) | 64 (61.0)    | 124 (76.1)| 271 |
| Collect from clinic to do at clinic***        | 13 (12.0) | 20 (19.0)    | 13 (8.0)  | 46  |
| Collect from clinic to do at home             | 11 (10.2) | 13 (12.4)    | 13 (8.0)  | 37  |
| Collect from pharmacy to do at home           | 6 (5.6)   | 4 (3.8)      | 5 (3.1)   | 15  |
| Collect from community laboratory to do at home| 3 (2.8)   | 1 (1.0)      | 2 (1.2)   | 6   |
| Return kit by courier***                      | 49 (45.4) | 28 (26.7)    | 74 (45.4) | 151 |
| Return kit to a clinic (such as family doctor)| 30 (27.8) | 39 (37.1)    | 49 (30.1) | 118 |
| Return kit to a community laboratory         | 22 (20.4) | 20 (19.0)    | 28 (17.2) | 70  |
| Return kit to a pharmacy                     | 11 (10.2) | 6 (5.7)      | 11 (6.7)  | 28  |

*NB Some women selected more than one response and some left the question blank; all responses were included.

***ps < 0.05 indicating a statistically significant effect of ethnicity on responses using a 3(ethnicity) × 2(selected reason or not) Pearson χ² test.
our own feasibility study to provide the first research that explores the preferences around HPV self-testing of Māori, Pasifika and Asian women who have actually used a self-testing kit. This study is timely for three reasons. First, the Aotearoa New Zealand Government has recently announced that they will invest “up to $53 million to … implement a new human papillomavirus (HPV) test” in 2023. The screening programme will introduce the option of either a self-test or clinician-taken sample to all women, which means that it is crucial that culturally relevant research and Māori, Pasifika and Asian expertise and knowledge are used to inform the design and roll-out of the new programme. Second, HPV self-testing has recently been announced as an option for participants in the Australian National Screening Programme from July 2022. Third, a recent editorial further suggests that the negative impact of the COVID-19 pandemic on cervical screening uptake may prove to be a tipping point for the wider introduction of self-testing. It is likely that Indigenous groups in other countries can benefit from these Aotearoa New Zealand findings.

To achieve elimination of cervical cancer as characterized by the WHO (4 cases per 100,000 women) incidence must be reduced by 63% for Māori women. This needs to be achieved by a concerted effort across primary care through HPV vaccination, cervical screening, diagnosis and treatment/follow-up pathways. Our findings indicate that HPV self-testing would offer an acceptable and culturally appropriate addition to the screening programme in Aotearoa New Zealand for Māori, Pasifika and Asian women – particularly if the preferences identified in our research are implemented – and thus has considerable potential to reduce inequities in access to screening and to save lives. Now that the Government has committed to rolling out HPV primary testing inclusive of self-testing, equity-focused approaches are required to ensure that benefits address the current and longstanding inequities in access to cervical screening and cervical cancer outcomes in Aotearoa New Zealand.

AUTHOR CONTRIBUTIONS
Karen Bartholomew: Conceptualization, funding acquisition, investigation, methodology, project administration, supervision, writing – review and editing. Naomi Brewer: Conceptualization, data curation, funding acquisition, investigation, methodology, project administration, supervision, writing – review and editing. Collette Bromhead: Conceptualization, funding acquisition, investigation, methodology, project administration, supervision, writing – review and editing. Jeroen Douwes: Conceptualization, funding acquisition, investigation, methodology, project administration, resources, supervision, writing – review and editing. Anna Maxwell: Conceptualization, investigation, methodology, project administration, supervision, writing – review and editing. John D. Potter: Conceptualization, funding acquisition, investigation, methodology, project administration, resources, supervision, writing – review and editing. Susan M. Sherman: Formal analysis, investigation, roles/writing – original draft, writing – review and editing. Chris Cunningham: Funding acquisition, investigation, methodology, writing – review and editing. Sue Crengle: Investigation, writing – review and editing. Sunia Foliaki: Funding acquisition, Investigation, writing – review and editing. Jane Grant: Conceptualization, investigation, writing – review & editing. Georgina McPherson: Funding acquisition, investigation, writing – review and editing. Nina Scott: Methodology, writing – review and editing. Helen Wihongi: Funding acquisition, investigation, methodology, writing – review and editing.

ACKNOWLEDGEMENTS
We thank the staff of the participating Primary Health Organizations and GP clinics, and all of the women who took part in our study. We thank Marion Saville (Victoria Cytology Service) and Susan Reid (Health Literacy NZ) for assistance with the design of the study materials and Mellissa Murray for assistance with interviews, project administration and coordination. Thanks are also due to the cultural advisory organizations: The Asian Network Inc (TANI), the Chinese New Settlers Trust and the Fono and individual advisors: Samantha Bennett, Raj Kumar, Leani Sandford and Sulu Samu. Thanks are also due to He Kamaka Waiora (Māori research services) and Waitemata DHB Asian Health Services, who were available to take queries from participating women. We would also like to acknowledge that screening data for the study were obtained from the NCSP Register, with approval. The National Kaitiaki Group granted approval for the use of Māori women’s data from the register and reviewed the study manuscript. This study was supported by Health Research Council of Aotearoa New Zealand (HRC 16/405).

CONFLICTS OF INTEREST
Naomi Brewer reports grants from Janssen-Cilag Pty Limited, outside the submitted work. Collette Bromhead has previously received educational funding to attend conferences from Roche Diagnostics New Zealand. Sue Crengle reports personal fees from Board member WelSouth Primary Health Network, personal fees from General Practitioner, Invercargill Medical Centre, personal fees from Board member, Royal NZ College of General Practitioners, outside the submitted work. H Wihongi reviews grants and other research applications from Waitemata District Health Board, outside the submitted work. She is also a member and convener of the National Kaitiaki Group. The remaining authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
As a result of ethics requirements and issues around data sovereignty associated with Indigenous people, at present, we are unable to share data.

ETHICS STATEMENT
The study was approved by the Aotearoa New Zealand Northern B Health and Disability Ethics Committee (HDEC) (reference: 17/NTB/120). The Aotearoa New Zealand Ministry of Health (including the National Kaitiaki Group—a group of Māori women established to monitor the safe use of Māori data within the NCSP) and the participating DHBs, Primary Health Organizations and clinics approved the use of data to identify and contact eligible women.
TRANSPARENCY DECLARATION

The authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.

ORCID

Susan M. Sherman  http://orcid.org/0000-0001-6708-3398
Naomi Brewer  http://orcid.org/0000-0003-4159-3570
Karen Bartholomew  http://orcid.org/0000-0002-1517-2134
Collette Bromhead  http://orcid.org/0000-0002-2890-2191
Sue Crenge  http://orcid.org/0000-0001-9367-1492
Jeroen Douwes  http://orcid.org/0000-0003-3599-4036
Sunia Foliaki  http://orcid.org/0000-0002-3238-5940
Jane Grant  http://orcid.org/0000-0003-2365-400X
Georgina McPherson  http://orcid.org/0000-0003-3550-4746
Nina Scott  http://orcid.org/0000-0002-9481-6400
Helen Wihongi  http://orcid.org/0000-0001-6801-6955
John D. Potter  http://orcid.org/0000-0001-5439-1500

REFERENCES

1. WHO. Human papillomavirus (HPV) and cervical cancer. 2020. Accessed May 1, 2021. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)–and-cervical-cancer

2. Bruni L, Albero G, Serrano B, et al. Human Papillomavirus and Related Diseases in New Zealand. Summary Report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 2019. Accessed August 19, 2021.

3. Ministry of Health. Immunisation Handbook. Ministry of Health; 2020.

4. National Screening Unit. Review of cervical cancer occurrences in relation to screening history in New Zealand for the years 2013-2017. 2020. Accessed May 1, 2021. https://www.nz.govt.nz/publications/review-cervical-cancer-occurrences-relation-to-screening-history-in-new-zealand-for-the-years-2013-2017

5. Enari D, Haua I, A Māori and Pasifika label—an old history, new context. Genealogy. 2021;5(3):70.

6. Brotherton J, Budd A, Saville M. Understanding the proportion of cervical cancers attributable to HPV. Med J Aust. 2020;3 212(2): 63-64.

7. TimeToScreen. Cervical screening. 2021. Accessed August 19, 2021. https://www.timetoscreen.nz/cervical-screening/

8. National Screening Unit. National Cervical Screening Programme Coverage Report. 2021. Accessed May 1, 2021. https://minh.ealthnz.shinyapps.io/nzscs-coverage/

9. Adcock A, Cram F, Lawton B, et al. Acceptability of self-taken vaginal HPV sample for cervical screening among an under-screened Indigenous population. Aust N Z J Obstet Gynaecol. 2019;59(2): 301-307.

10. Brewer N, Bartholomew K, Maxwell A, et al. Comparison of two invitation-based methods for human papillomavirus (HPV) self-sampling with usual care among un-and under-screened Māori, Pacific and Asian women: study protocol for a randomised controlled community trial to examine the effect of self-sampling on participation in cervical-cancer screening. BMC Cancer. 2019;19(1):1-10.

11. MacDonald EJ, Geller S, Sibanda N, et al. Reaching under-screened/never-screened indigenous peoples with human papilloma virus self-testing: a community-based cluster randomised controlled trial. Aust N Z J Obstet Gynaecol. 2021;61(1):135-141.

12. Bromhead C, Wihongi H, Sherman SM, et al. Human papillomavirus (HPV) self-sampling among never-and under-screened Indigenous Māori, Pacific and Asian women in Aotearoa New Zealand: a feasibility study. Int J Environ Res Public Health. 2021;18(19):10050.

13. Brewer N, Bartholomew K, Grant J, et al. Acceptability of human papillomavirus (HPV) self-sampling among never-and under-screened Indigenous and other minority women: a randomised three-arm community trial in aotearoa New Zealand. Lancet Reg Health West Pac. 2021;16:100265. doi:10.1016/j.lanwpc.2021.100265

14. Sultana F, Mullins R, English DR, et al. Women’s experience with home-based self-sampling for human papillomavirus testing. BMC Cancer. 2015;15:849.

15. Stemler S. An overview of content analysis. Pract Assess Res Eval. 2000;7(1):17.

16. Brewer N, Foliaki S, Bromhead C, et al. Acceptability of human papillomavirus self-sampling for cervical-cancer screening in under-screened Māori and Pasifika women: a pilot study. N Z Med J. 2019;132(1497):21-31.

17. Madzima TR, Vahabi M, Looters A. Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: focused literature review. Can Fam Physician. 2017;63(8):597-601.

18. Styffe C, Tratt E, Macdonald ME, Brassard P. HPV self-sampling in indigenous communities: a scoping review. J Immigr Minor Health. 2020;22:852-859.

19. Sandiford P, Buckley A, Robinson T, Tozer G, Holdsworth D, Badkar J. A community laboratory drop-off option for bowel screening test kits increases participation rates: results from an interrupted time series analysis. J Public Health. 2018;40(2): e133-e140.

20. Little A, Verrall A. Budget delivers improved cervical and breast cancer screening. 2021. Accessed May 9, 2021. https://www.beehive.govt.nz/release/budget-delivers-improved-cervical-and-breast-cancer-screening

21. Australian Government. Self collection to increase choice within the National Cervical Screening Program. 2021. Accessed January 30, 2022. https://www.health.gov.au/news/self-collection-to-increase-choice-within-the-national-cervical-screening-program

22. Lim AW. Will COVID-19 be the tipping point for primary HPV sampling? Cancer Epidemiol Biomarkers Prev. 2021;30(2):245-247.

23. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. Accessed February 16, 2022. https://www.who.int/publications/i Item/9789240014107

24. Whop LJ, Smith MA, Butler TL, et al. Achieving cervical cancer elimination among Indigenous women. Prev Med. 2021;144:106314.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Sherman SM, Brewer N, Bartholomew K, et al. Human papillomavirus self-testing among unscreened and under-screened Māori, Pasifika and Asian women in Aotearoa New Zealand: a preference survey among responders and interviews with clinical-trial nonresponders. Health Expect. 2022;25:2914-2923. doi:10.1111/hex.13599